Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2007

01-06-2007 | Educational Review

Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy

Authors: Tristan D. Yan, BSc (Med) MBBS, Junyang Sim, BSc (Med), David L. Morris, MD, PhD

Published in: Annals of Surgical Oncology | Issue 6/2007

Login to get access

Abstract

Background

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy has been suggested as a treatment option for patients with colorectal peritoneal carcinomatosis. However, the survival benefit is achieved at the expense of moderate to high perioperative morbidity and mortality.

Methods

This review summarized the important prognostic factors for survival; outlined the patient selection process from major peritonectomy centers, paying particular attention to preoperative evaluation; and identified areas for potential improvement. Emphasis was placed on a strict patient selection process to avoid futile aggressive treatments.

Results

Currently, contrast-enhanced computed tomography, magnetic resonance imaging, positron emission tomography, and laparoscopy have been utilized in the preoperative evaluation process to identify potential surgical candidates. Patients with good performance status, low volume of peritoneal disease, and absence of extra-abdominal metastases are more likely to benefit from the combined treatment.

Conclusions

Quantitative assessment of the extent of disease is possible and should be performed at the time of primary cancer operation. Careful selection of patients to identify surgical candidates with favorable prognostic indicators is important.
Literature
1.
Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502–8PubMedCrossRef
2.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42PubMedCrossRef
3.
Kabbinavar F, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697–705PubMedCrossRef
4.
Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23:4866–75PubMedCrossRef
5.
Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006;243:212–22PubMedCrossRef
6.
Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284–92PubMedCrossRef
7.
Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–43PubMedCrossRef
8.
Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006;24:4011–9PubMedCrossRef
9.
Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:376–80PubMed
10.
Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124–32PubMed
11.
Sugarbaker PH, Schellinx ME, Chang D, et al. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 1996;20:585–91PubMedCrossRef
12.
Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs delayed management. Dis Colon Rectum 2000;43:1341–6PubMedCrossRef
13.
Carmignani CP, Ortega-Perez G, Sugarbaker PH. The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer. Eur J Surg Oncol 2004;30:391–8PubMedCrossRef
14.
Gomes da Silva R, Sugarbaker P. Analysis of 10 prognostic factors in 70 patients having complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. Am J Coll Surg 2006;203:878–86CrossRef
15.
Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001;92:71–6PubMedCrossRef
16.
Hadi R, Saunders V, Utkina O, et al. Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg 2006;76:156–61PubMedCrossRef
17.
Shehata M, Chu F, Saunders V, et al. Peritoneal carcinomatosis from colorectal cancer and small bowel cancer treated with peritonectomy. ANZ J Surg 2006;76:467–71PubMedCrossRef
18.
Yan TD, Chu F, Links M, et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis—non-mucinous tumor associated with an improved survival. Eur J Surg Oncol 2006;32:1119–24PubMedCrossRef
19.
Kecmanovic DM, Pavlov MJ, Ceranic MS, et al. Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. Eur J Surg Oncol 2005;31:147–52PubMedCrossRef
20.
Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FAN. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004;91:739–46PubMedCrossRef
21.
Verwaal VJ, van Ruth S, Witkamp A, et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005;12:65–71PubMedCrossRef
22.
Glehen O, Cotte E, Schreiber V, et al. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004;91:747–54PubMedCrossRef
23.
Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multi-centric prospective study. Cancer 2000;88:358–63PubMedCrossRef
24.
Beaujard AC, Glehen O, Caillot JL, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000;88:2512–9PubMedCrossRef
25.
Glehen O, Osinsky D, Beaujard AC, Gilly FN. Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am 2003;12:729–39PubMedCrossRef
26.
Portilla A, Sugarbaker P, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg 1999;23:23–9PubMedCrossRef
27.
Gomes da Silva R, Cabanas J, Sugarbaker PH. Limited survival in the treatment of carcinomatosis from rectal cancer. Dis Colon Rectum 2005;48:2258–63PubMedCrossRef
28.
Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003;21:799–806PubMedCrossRef
29.
Loggie BW, Fleming RA, McQuellon RP, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000;66:561–8PubMed
30.
Shen P, Levine EA, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003;138:26–33PubMedCrossRef
31.
Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2004;11:178–86PubMedCrossRef
32.
Culliford A, Brooks A, Sharma S, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 2001;8:787–95PubMedCrossRef
33.
Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am 2003;12:649–71PubMedCrossRef
34.
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359–74PubMed
35.
Elias D, Delperro J-R, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004;11:518–21PubMedCrossRef
36.
Elias D, Raynard B, Farkhondeh F, et al. Peritoneal carcinomatosis of colorectal origin: long-term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery. Gastroenterol Clin Biol 2006;30:1200–4PubMed
37.
Yan TD, Links M, Glenn D, et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg 2006;93:1270–6PubMedCrossRef
38.
Yan TD, Sugarbaker P, Bijelic L. Critical analysis of treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. J Surg Oncol (in press)
39.
Yan TD, Brun E, Carlos A, Sugarbaker P. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007;14:41–9PubMedCrossRef
40.
Yan TD, Yoo D, Sugarbaker P. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006;32:948–53PubMedCrossRef
41.
Yan TD, Welch L, Black D, Sugarbaker P. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2006; doi:10.1093/annonc/mdl 428
42.
Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560–7PubMedCrossRef
43.
Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006;13:229–37PubMedCrossRef
44.
Brigand C, Monneuse O, Mohamed F, et al. Malignant peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal chemohyperthermia: results of a prospective study. Ann Surg Oncol 2006;13:405–12PubMedCrossRef
45.
Loggie BW, Fleming RA, McQuellon RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001;67:999–1003PubMed
46.
Verwaal VJ, Boot H, Aleman BMP, et al. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol 2004;11:375–9PubMedCrossRef
47.
Pilati P, Mocellin S, Rossi CR, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 2003;10:508–13PubMedCrossRef
48.
Elias D, Benizri E, Pocard M, et al. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol 2006;32:632–6PubMedCrossRef
49.
Nozoe T, Anai H, Nasu S, Sugimachi K. Clinicopathological characteristics of mucinous carcinoma of the colon and rectum. J Surg Oncol 2000;75:103–7PubMedCrossRef
50.
Papadopoulos VN, Michalopoulos A, Netta S, et al. Prognostic significance of mucinous component in colorectal carcinoma. Tech Coloproctol 2004;8(Suppl 1):s123–5PubMedCrossRef
51.
Kanemitsu Y, Kato T, Hirai T, et al. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum 2003;46:160–7PubMedCrossRef
52.
Kang H, O’Connell JB, Maggard MA, et al. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum 2005;48:1161–8PubMedCrossRef
53.
Du W, Mah JT, Lee J, et al. Incidence and survival of mucinous adenocarcinoma of the colorectum: a population-based study from an Asian country. Dis Colon Rectum 2004;47:78–85PubMedCrossRef
54.
Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FAN. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004;85:61–7PubMedCrossRef
55.
Yan TD, Alderman R, Edwards G, Sugarbaker P. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma—a prospective study of 70 consecutive cases. Ann Surg Oncol 2006
56.
Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 1993;113:631–6PubMed
57.
Younan R, Kusamura S, Baratti D, et al. Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2005;12:910–8PubMedCrossRef
58.
Kusamura S, Younan R, Baratti D, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006;106:1144–53PubMedCrossRef
59.
Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer 1993;72:1631–6PubMedCrossRef
60.
Tempany C, Zou K, Siverman S, et al. Staging of advanced ovarian: comparision of imaging modalities—report from the Radiological Diagnostic Oncology Group. Radiology 2000;215:761–7PubMed
61.
Davies J, Chalmers A, Sue-Ling H, et al. Spiral computed tomography and operative staging of gastric carcinoma: a comparision with histopathological staging. Gut 1997;41:314–9PubMedCrossRef
62.
de Bree E, Koops W, Kroger R, et al. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol 2004;86:64–73PubMedCrossRef
63.
de Bree E, Koops W, Kroger R, et al. Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2006;32:65–71PubMedCrossRef
64.
Jacquet P, Jelinek JS, Chang D, et al. Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg 1995;181:530–8PubMed
65.
Low RN, Barone RM, Lacey C, et al. Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium-containing contrast agents compared with unenhanced MR imaging and CT. Radiology 1997;204:513–20PubMed
66.
Low RN, Saleh F, Song SY, et al. Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination—a longitudinal study. Radiology 1999;211:519–28PubMed
67.
Low RN, Duggan B, Barone RM, et al. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. Radiology 2005;235:918–26PubMedCrossRef
68.
69.
Yan TD, Haveric N, Carmignani CP, et al. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005;103:839–49PubMedCrossRef
70.
Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol 2006;14:128–33PubMedCrossRef
71.
Huebner R, Park K, JE S, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177–89
72.
Pomel C, Appleyard T, Gouy S, et al. The role of laparoscopy to evaluate candidates for complete cytoreduction of peritoneal carcinomatosis and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005;31:540–3PubMedCrossRef
73.
Tozzi R, Kohler C, Ferrara A, Schneider A. Laparoscopic treatment of early ovarian cancer: surgical and survival outcomes. Gynecol Oncol 2004;93:199–203PubMedCrossRef
74.
Deffieux X, Castaigne D, Pomel C. Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer 2006;16:35–40PubMedCrossRef
75.
Gretschel S, Siegel R, Estevez-Schwarz L, et al. Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis. Br J Surg 2006;93:1530–5PubMedCrossRef
76.
Pomel C, Appleyard T, Gouy S, et al. The role of laparoscopy to evaluate candidates for complete cytoreduction of peritoneal carcinomatosis and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005;31:540–3PubMedCrossRef
Metadata
Title
Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy
Authors
Tristan D. Yan, BSc (Med) MBBS
Junyang Sim, BSc (Med)
David L. Morris, MD, PhD
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9350-7

Other articles of this Issue 6/2007

Annals of Surgical Oncology 6/2007 Go to the issue

Hepatic and Pancreatic Tumors

Optimization of Hyperthermic Intraperitoneal Chemotherapy With Oxaliplatin Plus Irinotecan at 43°C After Compete Cytoreductive Surgery: Mortality and Morbidity in 106 Consecutive Patients

Gynecologic Oncology

Determination of the Necessary Total Protein Substitution Requirements in Patients with Advanced Stage Ovarian Cancer and Ascites, Undergoing Debulking Surgery. Correlation with Plasma Proteins

OriginalPaper

Teaching Palliative Care and End-of-Life Issues: A Core Curriculum for Surgical Residents

Melanoma

Patterns of First-Recurrence and Post-recurrence Survival in Patients with Primary Cutaneous Melanoma After Sentinel Lymph Node Biopsy

Editorial

Retroperitoneal Sarcomas—An SOS to Colleagues in Europe

Breast Oncology

Axillary Reverse Mapping (ARM): A New Concept to Identify and Enhance Lymphatic Preservation